01 January 1999
Analysis of selected blood coagulation parameters and presence of cancer procoagulant (EC3.4.22.26) in patients with malignant neoplasms treated by surgery
Michał Tenderenda, Wojciech P. Mielicki, Jan Berner, Piotr RutkowskiMed Sci Monit 1999; 5(1): CR123-126 :: ID: 505272
Abstract
Cancer procoagulant is considered one of the most important factors responsible for blood coagulation disturbances, which often accompany malignancy. The presence of cancer procoagulant (EC 3.4.22.26) was examined in neoplastic tissues, which were collected from 25 patients (10 men, 15 women) who underwent surgical procedures due to malignant tumours located in different organs. Selected basic blood coagulation parameters (clotting time, prothrombin time, platelet count) were studied in blood samples of these patients. The presence of cancer procoagulant antigen was analysed by Western blotting with the use of polyclonal antibodies and blood coagulation parameters were verified by routine methods. CP antigen was detected in 23 (92%) out of 25 examined malignant tissues, including early stages. In 24 patients, no abnormalities of analysed clotting parameters were found. In one case, prolongation of clotting time and abnormal prothrombin time were detected. The presence of cancer procoagulant antigen in malignant tissue of patients with normal values of blood coagulation tests may suggest that the role of CP as a factor responsible for cancer-associated hypercoagulability can be additional. CP could still be responsible for generation of fibrin in situ, promoting tumour development. The results of this study confirm observation of other authors, that CP is a highly specific protein in different kinds of neoplasms and therefore, it could be a marker useful in the detection of cancer even in the early stages.
Keywords: coagulopathy, malignant neoplasms, cancer procoagulant
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952